ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trial...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, Rachel Layton, Jean Payne, Peter A. Durr, Hannah Bender, Jennifer A. Barr, John Bingham, Victoria Boyd, Sheree Brown, Matthew P. Bruce, Kathie Burkett, Teresa Eastwood, Sarah Edwards, Tamara Gough, Kim Halpin, Jenni Harper, Clare Holmes, William S. J. Horman, Petrus Jansen van Vuren, Suzanne Lowther, Kate Maynard, Kristen D. McAuley, Matthew J. Neave, Timothy Poole, Christina Rootes, Brenton Rowe, Elisha Soldani, Vittoria Stevens, Cameron R. Stewart, Willy W. Suen, Mary Tachedjian, Shawn Todd, Lee Trinidad, Duane Walter, Naomi Watson, Trevor W. Drew, Sarah C. Gilbert, Teresa Lambe, S. S. Vasan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/50b66ce00589424eb554445061a67484
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares